Cargando…

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossini, Anna, Giussani, Marta, Giacomini, Arianna, Guarnotta, Carla, Tagliabue, Elda, Balsari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483102/
https://www.ncbi.nlm.nih.gov/pubmed/23053664
http://dx.doi.org/10.1007/s10549-012-2281-4
_version_ 1782247941776343040
author Rossini, Anna
Giussani, Marta
Giacomini, Arianna
Guarnotta, Carla
Tagliabue, Elda
Balsari, Andrea
author_facet Rossini, Anna
Giussani, Marta
Giacomini, Arianna
Guarnotta, Carla
Tagliabue, Elda
Balsari, Andrea
author_sort Rossini, Anna
collection PubMed
description Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2(+) and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL(+) cells. Indeed, tumor cell “stemness”, assessed based on the proportion of CD44(+)/CD24(−/low) cells, was significantly correlated with susceptibility to TRAIL. Moreover, in vitro cytotoxicity experiments showed that CD34-TRAIL(+) cells selectively targeted CD44(+)/CD24(−/low) cells. Although in vivo treatment with CD34-TRAIL(+) cells did not lead to tumor growth inhibition, treated mice revealed significantly larger areas of necrosis associated with damage of tumor vasculature than did control mice. Moreover, lungs from MDA-MD-231 tumor-bearing mice were completely free of metastases at 12 days after the last injection of CD34-TRAIL(+) cells, whereas metastases were present in all control mouse lungs. An anti-metastatic effect of CD34-TRAIL(+) cells was also observed in a model of experimental lung metastases. The correlation between in vitro susceptibility to membrane-bound TRAIL and tumor stem cell content, together with CD34-TRAIL(+) cell-induced inhibition of the metastatic process, points to the selective targeting of cancer stem cells by CD34-armed cells and the potential value of such cells in eradicating tumor stem cells before the onset of overt metastases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-012-2281-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3483102
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-34831022012-11-05 Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model Rossini, Anna Giussani, Marta Giacomini, Arianna Guarnotta, Carla Tagliabue, Elda Balsari, Andrea Breast Cancer Res Treat Preclinical Study Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2(+) and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL(+) cells. Indeed, tumor cell “stemness”, assessed based on the proportion of CD44(+)/CD24(−/low) cells, was significantly correlated with susceptibility to TRAIL. Moreover, in vitro cytotoxicity experiments showed that CD34-TRAIL(+) cells selectively targeted CD44(+)/CD24(−/low) cells. Although in vivo treatment with CD34-TRAIL(+) cells did not lead to tumor growth inhibition, treated mice revealed significantly larger areas of necrosis associated with damage of tumor vasculature than did control mice. Moreover, lungs from MDA-MD-231 tumor-bearing mice were completely free of metastases at 12 days after the last injection of CD34-TRAIL(+) cells, whereas metastases were present in all control mouse lungs. An anti-metastatic effect of CD34-TRAIL(+) cells was also observed in a model of experimental lung metastases. The correlation between in vitro susceptibility to membrane-bound TRAIL and tumor stem cell content, together with CD34-TRAIL(+) cell-induced inhibition of the metastatic process, points to the selective targeting of cancer stem cells by CD34-armed cells and the potential value of such cells in eradicating tumor stem cells before the onset of overt metastases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-012-2281-4) contains supplementary material, which is available to authorized users. Springer US 2012-10-11 2012 /pmc/articles/PMC3483102/ /pubmed/23053664 http://dx.doi.org/10.1007/s10549-012-2281-4 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Preclinical Study
Rossini, Anna
Giussani, Marta
Giacomini, Arianna
Guarnotta, Carla
Tagliabue, Elda
Balsari, Andrea
Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title_full Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title_fullStr Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title_full_unstemmed Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title_short Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
title_sort surveillance of spontaneous breast cancer metastasis by trail-expressing cd34(+) cells in a xenograft model
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483102/
https://www.ncbi.nlm.nih.gov/pubmed/23053664
http://dx.doi.org/10.1007/s10549-012-2281-4
work_keys_str_mv AT rossinianna surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel
AT giussanimarta surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel
AT giacominiarianna surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel
AT guarnottacarla surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel
AT tagliabueelda surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel
AT balsariandrea surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel